Recruiting Clinical Trials

Pembrolizumab in Patients With Advanced Malignant Pleural Mesothelioma

By April 24, 2017 No Comments



Estimated Enrollment: 126

Age Group: 18 Years and older   (Adult, Senior)

Gender: All

Study Type: Interventional

Study Design Allocation: Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: No masking|Primary Purpose: Treatment

Study ID Numbers: I227|2016-002286-60

Study First Received: May 24, 2016

Last Updated: March 27, 2017

Estimated Primary Completion Date: May 2019


Primary Outcome Measures:

Progression free survival measured as time from randomization to first observation of objective disease relapse or progression|Number and severity of adverse events|Overall Survival|Quality of Life using EORTC QLQ-C30|Response rate compared using Fisher’s exact test

Sponsors and Collaborators:

Canadian Cancer Trials Group|National Cancer Institute, Naples|Merck Sharp & Dohme Corp.

Website Link:

Leave a Reply

Call Now